Silodosin: a review of its use in the treatment of the signs and symptoms of benign prostatic hyperplasia.

Article Details

Citation
Copy to clipboard

Keating GM

Silodosin: a review of its use in the treatment of the signs and symptoms of benign prostatic hyperplasia.

Drugs. 2015 Feb;75(2):207-17. doi: 10.1007/s40265-014-0344-z.

PubMed ID
25575983 [ View in PubMed
]
Abstract

Silodosin is a highly selective alpha1A-adrenoceptor antagonist indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Oral silodosin had a rapid onset of effect in men with lower urinary tract symptoms (LUTS) associated with BPH, with improvements seen in voiding and storage symptoms, maximum urinary flow rate and health-related quality of life in well-designed, 12-week trials. Silodosin was noninferior to tamsulosin in terms of improving LUTS associated with BPH. The efficacy of silodosin was maintained in 9-month extension studies and was also seen in a phase IV study conducted in a real-world setting. Silodosin was generally well tolerated and was associated with a low risk of orthostatic hypotension. Abnormal ejaculation was the most commonly reported adverse event, although few patients discontinued treatment with silodosin because of this adverse event. In conclusion, silodosin is a useful option for the treatment of LUTS associated with BPH.

DrugBank Data that Cites this Article

Drugs